Literature DB >> 24421439

Canagliflozin.

Dennis J Cada1, Kyle T Ingram2, Terri L Levien3, Danial E Baker4.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The November 2013 monograph topics are dolutegravir, levomilnacipran, ibrutinib, serelaxin, and polynuclear iron (III)-oxyhydroxide (PA21). The DUE/MUE is on dolutegravir.

Entities:  

Year:  2013        PMID： 24421439      PMCID： PMC3859282          DOI： 10.1310/hpj4810-855

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  11 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.

Authors:  S Sha; D Devineni; A Ghosh; D Polidori; S Chien; D Wexler; K Shalayda; K Demarest; P Rothenberg
Journal:  Diabetes Obes Metab       Date:  2011-07       Impact factor: 6.577

3.  Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Authors:  Paul Nyirjesy; Yue Zhao; Kirk Ways; Keith Usiskin
Journal:  Curr Med Res Opin       Date:  2012-06-14       Impact factor: 2.580

4.  Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.

Authors:  Lindsay E Nicolle; G Capuano; K Ways; K Usiskin
Journal:  Curr Med Res Opin       Date:  2012-05-15       Impact factor: 2.580

5.  Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

Authors:  D Devineni; L Morrow; M Hompesch; D Skee; A Vandebosch; J Murphy; K Ways; S Schwartz
Journal:  Diabetes Obes Metab       Date:  2012-02-08       Impact factor: 6.577

6.  Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Authors:  Sumihiro Nomura; Shigeki Sakamaki; Mitsuya Hongu; Eiji Kawanishi; Yuichi Koga; Toshiaki Sakamoto; Yasuo Yamamoto; Kiichiro Ueta; Hirotaka Kimata; Keiko Nakayama; Minoru Tsuda-Tsukimoto
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

7.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Authors:  Wei Meng; Bruce A Ellsworth; Alexandra A Nirschl; Peggy J McCann; Manorama Patel; Ravindar N Girotra; Gang Wu; Philip M Sher; Eamonn P Morrison; Scott A Biller; Robert Zahler; Prashant P Deshpande; Annie Pullockaran; Deborah L Hagan; Nathan Morgan; Joseph R Taylor; Mary T Obermeier; William G Humphreys; Ashish Khanna; Lorell Discenza; James G Robertson; Aiying Wang; Songping Han; John R Wetterau; Evan B Janovitz; Oliver P Flint; Jean M Whaley; William N Washburn
Journal:  J Med Chem       Date:  2008-02-09       Impact factor: 7.446

8.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Authors:  K Stenlöf; W T Cefalu; K-A Kim; M Alba; K Usiskin; C Tong; W Canovatchel; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-01-24       Impact factor: 6.577

9.  Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Authors:  Julio Rosenstock; Naresh Aggarwal; David Polidori; Yue Zhao; Deborah Arbit; Keith Usiskin; George Capuano; William Canovatchel
Journal:  Diabetes Care       Date:  2012-04-09       Impact factor: 19.112

10.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Authors:  J-F Yale; G Bakris; B Cariou; D Yue; E David-Neto; L Xi; K Figueroa; E Wajs; K Usiskin; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-03-28       Impact factor: 6.577
View more
  2 in total

Review 1.  Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management.

Authors:  André Gustavo P Sousa; João Victor de Sousa Cabral; William Batah El-Feghaly; Luísa Silva de Sousa; Adriana Bezerra Nunes
Journal:  World J Diabetes       Date:  2016-03-10

Review 2.  Diabetes mellitus and electrolyte disorders.

Authors:  George Liamis; Evangelos Liberopoulos; Fotios Barkas; Moses Elisaf
Journal:  World J Clin Cases       Date:  2014-10-16       Impact factor: 1.337
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.